. [eighty two] to evaluate the efficacy, basic safety and tolerability of Cannabidiol as an adjunct therapy in addition to anti-epileptic drugs to the people suffering from tuberous sclerosis sophisticated whose most common neurological symptom is epilepsy. With this clinical demo research, righ